Cipher Pharmaceuticals Inc.
CPHRF
$8.95
$0.303.47%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 140.28% | 70.90% | 0.30% | 20.08% | 0.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 140.28% | 70.90% | 0.30% | 20.08% | 0.22% |
| Cost of Revenue | 437.07% | 83.09% | 4.24% | 7.98% | 2.03% |
| Gross Profit | 68.80% | 68.27% | -0.69% | 23.10% | -0.20% |
| SG&A Expenses | 274.65% | 172.49% | 4.36% | 24.51% | 25.88% |
| Depreciation & Amortization | 453.48% | 615.61% | -14.62% | -15.74% | -19.94% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 350.33% | 179.15% | -1.70% | 12.39% | 9.16% |
| Operating Income | -85.90% | -38.14% | 2.49% | 28.15% | -7.89% |
| Income Before Tax | -177.53% | -89.56% | -20.66% | 9.60% | 25.46% |
| Income Tax Expenses | -55.96% | 101.10% | -584.85% | -2,484.15% | 76.27% |
| Earnings from Continuing Operations | -56.32% | -95.97% | -2.47% | 87.47% | -61.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.32% | -95.97% | -2.47% | 87.47% | -61.10% |
| EBIT | -85.90% | -38.14% | 2.49% | 28.15% | -7.89% |
| EBITDA | -34.55% | 15.28% | 0.45% | 22.63% | -9.63% |
| EPS Basic | -58.81% | -95.97% | 2.48% | 96.18% | -59.72% |
| Normalized Basic EPS | -151.27% | -38.78% | -13.59% | 13.18% | 29.86% |
| EPS Diluted | -57.17% | -96.30% | 0.00% | 100.00% | -60.43% |
| Normalized Diluted EPS | -152.37% | -39.00% | -13.80% | 13.10% | 29.25% |
| Average Basic Shares Outstanding | 6.05% | -0.53% | -4.84% | -4.47% | -3.42% |
| Average Diluted Shares Outstanding | 3.81% | -0.02% | -4.49% | -4.53% | -2.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |